Telotristat etiprate

Drug Profile

Telotristat etiprate

Alternative Names: LP-778914 (free base); LX 1032; LX 1606; LX1032 hippurate; LX1606 hippurate; Telotristat ethyl; Telotristat ethyl hippurate; Xermelo

Latest Information Update: 25 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Lexicon Pharmaceuticals
  • Developer Ipsen; Lexicon Pharmaceuticals
  • Class Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Serotonin modulators; TPH1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant carcinoid syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant carcinoid syndrome
  • Discontinued Ulcerative colitis

Most Recent Events

  • 21 Jul 2017 Updated efficacy and safety data from the phase III TELESTAR and TELECAST trial in Malignant carcinoid released by Ipsen
  • 21 Jul 2017 CHMP of EMA adopts a positive opinion for the marketing authorisation of telotristat etiprate in Malignant carcinoid syndrome
  • 02 Jun 2017 Efficacy and safety data from the phase III TELESTAR trial in Malignant carcinoid syndrome presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top